Deuteration as a Tool for Enhancing the Half-Life of Drug

Vijay Kumar, Archana Dhyani, N Singh

Abstract: The aim of the article is that deuteration of any compounds leads to the enhancement of metabolic activity. The substitution of Carbon-Hydrogen bond by Carbon–Deuterium helps for enhancing pharmacokinetic profile of the drug. Since C-D bond is ten time more tough to C-H bond. Nowadays, many drug molecules are deuterated to increase the residence time of the drug as well as diminishing the metabolism of the drug. Deuterated drugs also finds various therapeutic applications. The deuterated drugs is also approved by Food and Drug Administration. The deuteration helps in increasing the dwell time of the drug and reducing frequency of dosing.

Keywords: Deuteration, half-life, pharmacokinetics, therapeutic effects

I. INTRODUCTION

Drug research and development is a more difficult process because of increased cost and risk associated with the process. (1)Deuterium is a isotope of water containing 0.015% deuteriumoxide. In nuclear reactors it is basically used as moderators. (2)When living systems are exposed to D2O the two effects are basically arises. One is due to effect of D2O itself and the second affect is due to capability to substitute hydrogen withdeuterium in body. The carbon–deuterium bond resistant to enzymatic cleavage as compared to C-H bond. The compounds containing C-D bonds are more stable than compounds containing C-H bond. (3) D2O also has numerous therapeutic applications and it is used as therapeutic agent against pancreatic cancer, stability of cells and tissues, stability of macromolecules and helps in determination of total body water. (4) Recently, a number of patents are granted or filed regarding the potential therapeutic applications of D2O.(5)

II. THERAPEUTIC APPLICATION OF DEUTERATED COMPOUNDS

The deuterated drug can be used in the treatment of various human diseases. Edward M. Russak et al (2018) studied that first deuterated drugs Deuterobenzamine which is deuterated form of tetrabenzamine. Deuterobenzamine is the drug which is accepted by Food and Drug Administration (FDA) and the drug is used in the treatment of Huntington’s disease and tardive dyskinesia. (6) The deuterated drug is also responsible for improved metabolism of drug. The another study which was done by Graham S Timmins et al (2014) who studied that transformation of drugs into deuterated forms has better pharmacokinetic or toxicological properties. This is because due to the presence stronger deuterium-carbon bond which is responsible for their improved metabolism. The ability of deuterium oxide for treatment of various diseases, use of deuterium oxide in experiments, artificial synthesis of deuterium-labeled compounds was studied by Wendell Costa Bila (2017).(7)

Deuterated Etavirenz finds use for nephrotoxicity. Scott L. Harbeson et al (2014) studied that the deuterated refavirenz to clarify the nephrotoxicity in mice. Etavirenz is an inhibitor of reverse transcriptase which is used for treatment of HIV. The substitution of hydrogenof cyclopropylmethineby means of deuterium, thus dropping the metabolism and reduces the severity of nephrotoxicity. (8)

The secondary amines can be useful in synthesis of larger polymers and organic molecules. The study on optoelectronic devices was done by Anwen M. Krause-Heuer 2014. The production of organic molecules or polymers can be done by using deuterated arylamines (9). A study was done by Robert B. Raffael et al (2018) in which he studied that the (C-H) bond has less stability in comparison to C-D bond. It was found that if deuterium is located suitably in drug so the carbon deuterium bond does not undergo metabolic breakdown which leads to enhance the stability of the drug (10).

Similarly, a study was done by Sarah Cargnin (2019) which revealed that there are many deuterated drugs in clinical development stage. About 20 drugs are under this stage in which 6 drugs reaches the III phase clinical trials. Through out previous years more focus is given to the deuterated drugs and in 2018, novel drug, HC-1119, enter in clinical development of deuterated drug (11).

Another important study was done by Sukhinder Kauret et al (2017) where it was emphasized that deuteration take part in enhancing half life of drug. The bond formation between carbon hydrogen is weak as compared to carbon with deuterium. This ultimately leads to increase in the biological half-life of the drug (12). Cuibo Liu (2018) researched the halides deuteration using heavy water. The deuteration strategy show improved results and tolerances. The deuterated acids and alkenes are useful in various reactions like suzuki coupling and click reaction, for production of multifaceted deuterated compound (13). Raman Sharma et al (2012) studied that the pharmacokinetic profile of drugs can be altered by means of deuterium.
Deuteration as a Tool for Enhancing the Half-Life of Drug

It was found that the ex-vivo and in-vivo methods suggested that the deuterated carbazeran and zoniporide have decreased metabolism and it helps in increasing the half life of the drugs. Malgorzata Cebo (2014) et al investigated that the exchange in D-H in imidazole gets affected by phosphorylation of histidine side chain in peptides. The consequences reveal that phosphorylation considerably slows the speed of the DHX reaction. (14)

Maicon Guerra de Miranda developed deuterated compound which is frequently used as biomarkers in petroleum and related sample. (15) The benzopyran deuterated was prepared by Yanmei Zhang, Micky D. Tortorella et al. (2014). It is used as a novel inhibitor of COX-2. The compound has better pharmacokinetic profile than the previous one. The novel compound shows effective role in various inflammatory and painful conditions. (16)

In 2016 Jinfang Jiang et al studied that the Enzalutamide (ENT) which is responsible for inhibition of the androgen receptor was accepted from management of prostate cancer by US FDA. In this the N-CH3 moiety were substituted by deuterium. This shows that the drug has good pharmacokinetic profile. (17)

III. CONCLUSION

The article concluded that the deuteration is a vital factor in enhancing half-life of the drug. The deuterated drugs takes more time to get cleared from the systemic circulation. It helps to increase the residential of drug inside the body and thus helpful in reducing the dosing regimen which can ultimately leads to enhance the dosage regimen.

REFERENCES

1. Jing Chen, Xiaofang Luo, Huimin Qiu, Vienna Mackey, Lichun Sun, Xiaoping Ouyang, M. Drug discovery and drug marketing with the critical roles of modern administration, Am J Transl Res 2018;10(12):4302-4312.
2. Benedict, M., Piggford, T.H., and Levi, H.W. Nuclear chemical engineering. 2nd ed. McGraw-Hill, New York, 1981:1006.
3. J.Katz, J.J. 1960. The biology of heavy water. Sci. Am. 203: 106-115.
4. Chauhan P. 2016. Heavy water: alternative applications in biology, medicine and industry.
5. Chauhan P. 2016. Heavy water: alternative applications in biology, medicine and industry.
6. Edward M. Russak, Edward M. Bednarczyk, Impact of Deuteration on the Pharmacokinetics of Pharmaceuticals, Annals of Pharmacother 1-6, 2018.
7. Graham S Timmins, Deuterated drugs; where are we now?, Expert Opin Ther Pat. 2014 October; 24(10): 1067–1075.
8. Scott L. Harbeson, Roger D. Tung, Deuterium Medicinal Chemistry: A New Approach to Drug Discovery and Development, Medchem News No.2, 2014:8-22.
9. Arwen M. Krause-Heuer, Nageshwar R. Yepuri, Tamim A. Darwishand Peter J. Holden, Mild Conditions for Deuteration of Primary and Secondary Arylamines for the Synthesis of Deuterated Optoelectronic Organic Molecules, Molecules 2014, 19, 18604-18617.
10. Robert B. Raffa, Joseph V. Pergolizzi, Robert Taylor, The First Approved “Deuterated” Drug: A ShortReview of the Concept, Pharmacology & Pharmacy, 2018, 9, 440-446.
11. Sarah Cargnin, Marta Serafini & Tracey Perali, A primer of deuterium in drug design, Future Med. Chem. 2019,11(16), 2039–2042.
12. Sukhinder Kaur and Monika Gupta, Deuteration as a Tool for Optimization of Metabolic Stability and Toxicity of Drugs, Global journal of Pharmacy & pharmaceutical Sciences, 1(4) 2017, 1-11.
13. Cuibo Liu, Zhongxin Chen, Chening Su, Xiaoxu Zhao, Qiang Gao, Controllable deuteration of halogenated compounds by photocatalytic D2O splitting, Nature Communications, (2018) 9:80